Loading clinical trials...

Treatment for Presumed Ocular Histoplasmosis | Clinical Trials | Clareo Health

UNKNOWNPhase 1/2NCT01790893

Treatment for Presumed Ocular Histoplasmosis

The purpose of this study is to monitor safety outcomes for patients being treated with intravitreal aflibercept injections for choroidal neovascularization secondary to Presumed Ocular Histoplasmosis...

Lead sponsor: John Kitchens, MD•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Diana Holcomb, COA

CONTACT

859-264-2905 dholcomb@retinaky.com

Related studies

COMPLETEDPhase 1

Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome

NCT01578720 · Choroidal Neovascularization, Presumed Ocular Histoplasmosis

UNKNOWNPhase 1/2

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

NCT00955630 · Ocular Histoplasmosis Syndrome

UNKNOWNPhase 2

Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

NCT00546936 · Presumed Ocular Histoplasmosis (POHS)

TERMINATEDNA

Macugen for Histoplasmosis

NCT00272766 · Ocular Histoplasmosis, Choroidal Neovascularization

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 16, 2014Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE1/PHASE2

Enrollment40

Start dateMar 2013

Last updatedJun 16, 2014

Condition

Ocular Histoplasmosis

Locations shown

Southeast Retina

Augusta, Georgia

Retina Associates of Kentucky

Lexington, Kentucky

Cincinnati Eye Institute

Cincinnati, Ohio

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 16, 2014Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions